Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
NCT03245190 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27
Last updated 2021-06-18
Summary
Chiauranib, which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Conditions
Interventions
- DRUG
-
Chiauranib
50mg, orally once daily
Sponsors & Collaborators
-
Chipscreen Biosciences, Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-28
- Primary Completion
- 2019-11-01
- Completion
- 2019-11-01
Countries
- China
Study Locations
More Related Trials
-
Evaluating Patients With Impaired Hepatic Function
NCT00398424 ·Status: COMPLETED ·Phase: PHASE1
-
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
NCT05010681 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
NCT06618664 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
NCT05557838 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
NCT03794440 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.
NCT05673824 ·Status: COMPLETED ·Phase: PHASE2
-
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
NCT05770882 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
NCT05797805 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
NCT00712790 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
NCT01897038 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy
NCT00933816 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
NCT04560894 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
NCT04042805 ·Status: UNKNOWN ·Phase: PHASE2
-
IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
NCT06757881 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
NCT03941873 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
NCT04072679 ·Status: COMPLETED ·Phase: PHASE1
-
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT05883644 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT02576509 ·Status: COMPLETED ·Phase: PHASE3
-
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
NCT06375642 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
NCT01932385 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
NCT00790218 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
NCT05603039 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
NCT01540461 ·Status: COMPLETED ·Phase: PHASE1
-
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
NCT05257590 ·Status: RECRUITING ·Phase: PHASE2